Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 2:41 PM
Ignite Modification Date:
2025-12-24 @ 2:41 PM
NCT ID:
NCT01156259
Eligibility Criteria:
Inclusion Criteria:
* biopsy-proved Diffuse Large B cell lymphoma
* nonbulky stage I, nonbulky stage IE, nonbulky stage II, or nonbulky stage IIE disease(Bulky disease was defined as a mass 10 cm or more in maximal diameter) according to Ann Arbor Staging
* provide written informed consent
* Complete regression after chemotherapy
* Considerable to CT simulation and 3D CRT or IMRT
* Performance status 0-2 WHO criteria；life expectation\>6 months
* negative for human immunodeficiency virus syndrome (HIV)
* Minimal staging included chest radiograph, computed tomography of the abdomen and pelvis, and single percutaneous bone marrow biopsy and blood studies
Exclusion Criteria:
* primary mediastinal large B cell lymphoma
* dermatological lymphoma
* testicular lymphoma
* primary central nerve system lymphoma
* prior RT
* history of low-grade lymphoma congestive
* history of heart failure (CHF; New York Heart Association \[NYHA\] classifications III-IV), history of neoplasm (adequately treated basal cell carcinoma of the skin or in situ carcinoma of the uterine cervix were allowed), abnormal liver function tests (aminotransferases and alkaline phosphatase \> 2.5 times the upper limit of normal, bilirubin \> 50 ), renal insufficiency (serum creatinine \> 300 ), and patients with any serious medical or psychiatric illness that would prevent informed consent or completion of protocol-prescribed treatment and follow-up
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
15 Years
Study:
NCT01156259
Study Brief:
Protocol Section:
NCT01156259